FilingSEC EDGAR8-K
Tenax Therapeutics Pauses Enrollment in LEVEL-2 Clinical Trial
· SEC accepted
StagePhase 3
Filing content
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 clinical trial to amend criteria based on LEVEL trial findings and has requested a Type C meeting with the FDA.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…